This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Study of Avastin (Bevacizumab) in Combination With Neoadjuvant Treatment Regimens in Patients With Primary HER2 Negative Breast Cancer

This study is ongoing, but not recruiting participants.
Norwegian Radium Hospital
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: October 15, 2008
Last updated: August 1, 2016
Last verified: August 2016
This 2 arm study will evaluate the effect of Avastin, in combination with chemotherapy or endocrine therapy, as preoperative treatment in patients with HER2 negative breast cancer. Patients will be randomized to receive either chemotherapy (FEC100 for 4 x 3weekly cycles or endocrine therapy (an aromatase inhibitor daily for 24 weeks)with or without Avastin (15mg/kg iv every 3 weeks).The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.

Condition Intervention Phase
Breast Cancer Drug: Placebo Drug: Standard chemotherapy or endocrine therapy Drug: bevacizumab [Avastin] Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, ph II Clinical Trial to Evaluate the Effect of Avastin in Combination With Neoadj Treatment Regimens on the Molecular and Metabolic Characteristics and Changes in the Primary Tumors With Ref to the Obtained Responses in Patients With Large Primary HER2 Neg Breast Cancers

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • MRI determinants of pathological complete response [ Time Frame: Throughout study ]

Secondary Outcome Measures:
  • Molecular changes in protein kinase, mRNA/miRNA and protein expression; SNP profiles predicting treatment response; treatment-induced changes in tumor cells. [ Time Frame: Thoughout study ]

Enrollment: 150
Study Start Date: November 2008
Estimated Study Completion Date: January 2023
Estimated Primary Completion Date: January 2023 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Standard chemotherapy or endocrine therapy
As prescribed
Drug: bevacizumab [Avastin]
15mg/kg iv every 3 weeks
Placebo Comparator: 2 Drug: Placebo
iv every 3 weeks
Drug: Standard chemotherapy or endocrine therapy
As prescribed


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adult patients, >=18 years of age;
  • HER2-negative breast cancer, >=2.5cm in size;
  • ECOG/WHOperformance status <=2;
  • normal baseline cardiac function (LVEF).

Exclusion Criteria:

  • stage IV (metastatic) disease;
  • previous treatment for localized breast cancer < 24 months from diagnosis of present breast cancer;
  • other previous or current cancer except for basal cell cancer or in situ cervical cancer;
  • current or recent use of aspirin (>325mg/day);
  • clinically significant cardiovascular disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00773695

Oslo, Norway, 0379
Oslo, Norway, 0407
Trondheim, Norway, 7000
Sponsors and Collaborators
Hoffmann-La Roche
Norwegian Radium Hospital
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT00773695     History of Changes
Other Study ID Numbers: ML21744
Study First Received: October 15, 2008
Last Updated: August 1, 2016

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antineoplastic Agents processed this record on August 23, 2017